Genyous Biomed

James Dao, Co-founder, Chairman of the Board & CEO

James Dao is a successful high tech inventor and entrepreneur based in Silicon Valley with over 35 years of experience in managing, inventing, developing, and commercializing advanced technologies and innovative applications.

As founder and CEO of entrepreneurial companies, Mr. Dao is known for commercializing visionary business concepts and innovative products that stimulated paradigm shifts in their industries. These companies (in instrumentation, semiconductors and software) reached market capitalizations of US$2.7 billion and US$750 million respectively. Mr. Dao's technical accomplishments include developing next generation scanning electron beam microscopes that overcame previous limitations and allowed cancer research to progress since the 1970s. Mr. Dao also participated in the design of a pioneering machine that used radiation to treat cancer (now Varian's medical instrument division). Since the inception of Genyous Biomed, Mr. Dao has served as chief executive officer. He conceived the need for a paradigm change in therapeutics for the prevention and treatment of cancer. Mr. Dao personally recruited the multi-disciplinary scientific/engineering team and lead the research and development of Multifunctional Multitargeted (MFMT) therapies to prevent and treat cancer and other chronic diseases.

Dr. David Alberts M.D., Board Member, Chief Clinical Science Officer

Dr. David Alberts currently serves as director of the Arizona Cancer Center at the University of Arizona and is a recognized leader in research in the prevention of cancer. He is a Regents Professor of Medicine, Pharmacology, Nutritional Sciences, Public Health, and BIO5 Institute, the University of Arizona, Tucson, Arizona. Dr. Alberts has been funded by the National Cancer Institute (NCI) yearly since 1971 for laboratory and clinical research related to the clinical pharmacology of cancer chemotherapy and chemopreventive agents, as well as the development of research strategies for the prevention of breast, cervix, colon, prostate and skin cancers. Since 1987, Dr. Alberts has served as the principal investigator for two NCI-funded cancer prevention program project grants: the Colon Cancer Prevention Program Project and the Chemoprevention of Skin Cancer Program Project.

Dr. Alberts has authored or co-authored more than 400 peer-reviewed publications, has served as editor and co-editor of four books and has served on several editorial boards. Dr. Alberts also serves as Genyous' Chief Clinical Science Officer. Dr. Alberts plays a leadership role in shaping Genyous' clinical research in cancer detection, prevention and treatment.

Jeffrey Dao, Board Member

Mr. Dao has over twenty years of experience in the creation and management of emerging technology and new business development. Mr. Dao began his career as an application engineer at Communication Intelligence Corporation (CIC), a leading developer of pattern recognition technologies. Over a period of 10 years, Mr. Dao became CIC's head of marketing and sales and contributed to the company's successful IPO on Nasdaq. Mr. Dao also served as Senior Director of Business Development for Oracle Corporation where he helped to build strategic alliances to support the company's CRM and e-Business objectives. Mr. Dao also served as Vice President of Business Development at Nokia Inc., where he managed acquisitions and built strategic alliances to support the company's Internet-communications objectives.

Mr. Dao is a co-founder of Genyous Biomed and President and COO of Omnitura Therapeutics Inc., a Genyous commercialization affiliate.

Dr. Abhay Joshi, Ph.D., Board Member

Dr. Abhay Joshi currently serves as President, CEO and Director of Alvine Pharmaceuticals. He has over eighteen years of global operations and research and development experience in biologic, pharmaceutical and medical device industries in the United States, Europe, Latin America and Asia Pacific. Previously, Dr. Joshi served as an Executive Vice President, Chief Technical Officer and member of the Executive Committee at CoTherix, Inc., now Actelion Ltd. Prior to CoTherix, Dr. Joshi was the Vice President of Global Technical Operations, Specialty Pharmaceuticals at Allergan where he was responsible for the company's global biologics manufacturing operations for BOTOX® and its Latin America and Asia Pacific pharmaceutical operations. Dr. Joshi received his BTech in Chemical Engineering from the Indian Institute of Technology, New Delhi, an MSE and a Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, and an MBA from the University of California, Irvine. Dr. Joshi holds an adjunct faculty appointment at the University of Southern California School of Pharmaceutical Sciences.

David Korbin, Board Member

Mr. David Korbin presently works as a management and financial consultant. He is a director of E-Comm Emergency Communications for Southwest British Columbia. He has been Chairman of E-Comm's board of directors since 2004 and was Chairman of the audit committee from 2002 to 2003. From 1992 to 2000, he was a director of the Vancouver General Hospital and then the Vancouver Hospital and Health Sciences Centre, serving as Chairman of the Vancouver General Hospital audit committee from 1993 to 1994 and Chairman of the Vancouver Hospital and Health Sciences Centre from 1995 to 1998. Mr. Korbin qualified as a Chartered Accountant in 1966, and from 1990 to 1992 he was a managing partner of Deloitte Touche LLC. Mr. Korbin also is a director of Ivanhoe Mines (NASDAQ: IVN) and Seaspan Corporation (NYSE: SSW), and is Chairman of Seaspan's Audit Committee. Mr. Korbin became a director of Genyous in November 2007 and is a member of Genyous' Audit Committee.

Jerry Norskog, Board Member

Mr. Norskog has over thirty years of experience in the pharmaceutical industry. Mr. Norskog held numerous senior management positions for various divisions of Johnson & Johnson in North America and throughout Asia Pacific. His Asia experience includes serving as president of Xian-Janssen Pharmaceutical Ltd, a Johnson & Johnson joint venture with the Chinese Government, which was ranked among the top ten best ventures in China since 1991. Mr. Norskog also served as President of Johnson & Johnson China Development. Mr. Norskog's most recent engagement was as President of McNeil Consumer Healthcare, the division of Johnson & Johnson which markets Tylenol. Mr. Norskog is Chairman emeritus of the Chinese Foreign Pharmaceutical Investment Association. As a member of the Genyous board of directors, Mr. Norskog provides valuable insight on the global pharmaceutical markets and guidance on the cultivation of joint ventures and manufacturing & distribution alliances.

Dr. John Ostrem, Ph.D., Board Member

Dr. John Ostrem has more than 30 years experience inventing new technology and bringing products to market. In 1982, he co-founded Communication Intelligence Corporation, a company specializing in natural input and electronic signature solutions where he served for 15 years as CTO and Senior VP of Research and Engineering. Subsequently Dr. Ostrem was Vice-President of R&D and Engineering at Dejima, a company that created and deployed user-friendly natural language interfaces. In 2001 Dr. Ostrem co-founded China MobileSoft, a company that developed telecommunications software for the Chinese and International markets, and at various times served as Chairman, CEO, and CTO. China MobileSoft's software was integrated into over 80 products. Dr. Ostrem oversaw the acquisition of China MobileSoft by PalmSource (the maker of the software used in the market leading Palm PDAs and smart phones). Dr. Ostrem began his career as a scientist and researcher at SRI (the former Stanford Research Institute). Dr. Ostrem has many scientific publications, patents, and has received numerous grants and awards from the National Science Foundation and NIST. As a member of the Genyous board of directors, Dr. Ostrem provides guidance on the medical application of nanotechnology and strategy regarding research funding.

Lee Ting, Board Member

Mr. Ting currently serves as Managing Director of WR Hambrecht+Co, an investment bank based in San Francisco. He is an independent Board Member of the Lenovo Group, a leading IT company in China, and MTI, a global supplier of satellite/microwave communications components and subsystems based in Taiwan. Mr. Ting is a former Corporate Vice President of Hewlett Packard Co. (HP) where he worked for more than thirty years. His last position at HP was Corporate Vice President and Managing Director of Worldwide Geographic Operations. During a two-year absence from HP in the late eighties, Lee was a Senior Vice President of Hambrecht & Quist where he played a key role in the expansion of the firm's venture capital business into Asia.

Francis Dane, Esq, Corporate Secretary/Treasurer

Mr. Francis Dane brings a unique combination of legal and public accounting perspective and experience to Genyous. Mr. Dane has spent more than twenty years serving companies, in numerous capacities, at various stages of their development from start-up to public offering. Mr. Dane's other experiences include serving at various times as the chief legal officer, vice president, and chief financial officer for Communication Intelligence Corporation (CIC) from 1988 to present. He also served on the board of directors of CIC Japan. Prior to CIC, Mr. Dane also spent over a decade with PriceWaterhouseCoopers, completing his tenure with that company as the senior manager of entrepreneurial services based in the Silicon Valley office in San Jose, California.

George Burke, Esq, Assistant Corporate Secretary

Mr. George Burke is also a partner with the Canadian law firm Blake, Cassels & Graydon. Mr. Burke practices business law with a special emphasis on mergers and acquisitions, and corporate project and venture capital financing. Throughout his career, he has lead acquisitions, divestitures and financings in a diverse range of industries, including transportation, technology, forestry, food services, and hotel and resort. Mr. Burke has also been involved in the structuring of several investment funds and assisted those funds with the acquisition of portfolio companies. He has negotiated major international business transactions in Europe, the United States and Asia, particularly in the area of ship construction, acquisition, finance and chartering.

Dr. Larry Goldenberg, M.D., Chief Medical Officer, Urology

Dr. Goldenberg is Professor and Chairman of the Department of Urologic Sciences at UBC, Director of Clinical Research at the Prostate Centre at Vancouver General Hospital, and a Fellow of the Canadian Academy of Health sciences. He is a co-founder of the Canadian Urologic-Oncology Group, and past-president of both the Canadian Urological Association and the Western section of the American Urological Association.

Through his vision and leadership, the Prostate Centre at Vancouver General Hospital has developed into one of the top prostate research, education and healthcare delivery programs in the world. Dr. Larry Goldenberg was a pioneer in the use of intermittent hormone withdrawal for the management of prostate cancer, which is now used worldwide as a treatment option for this disease. His book, Prostate Cancer - All You Need to Know to Take an Active Part in Your Treatment, is considered one of the best reference sources for men with prostate disease in North America.

Dr. Stephen Lam, M.D., Chief Medical Officer, Pulmonary

Dr. Lam is a doctor of pulmonary medicine and is also Professor of Medicine at the University of British Columbia. Dr. Lam also serves as Chairman of the Lung Tumour Group at the BC Cancer Agency. He has served on the advisory committees at the U.S. Department of Health and the National Cancer Institute in functional imaging, biomarkers and chemoprevention committees. He is an advisor to the University of Texas Southwestern Medical Center and the University of Colorado for their Specialized Program of Research Excellence in Lung Cancer. He was the past president of the International Photodynamic Association, Regent of the World Association of Bronchology, and Governor of the American College of Chest Physicians in British Columbia. He is the principal investigator of several U.S. NCI sponsored Phase I and Phase II clinical trials of chemopreventive agents that include both prescription drugs and natural products. He has published over 150 peer-reviewed articles, 11 patents and 27 book chapters. He is recognized as one of the world’s leading experts in early lung cancer detection and chemoprevention.

Dr. Lam is also internationally recognized for his 25 years of scientific research in early lung cancer detection and chemoprevention. He is the co-inventor of the autofluorescence bronchoscopic device for localization of pre-neoplastic lesions and early lung cancer. The technology has been adopted by major endoscope companies worldwide. In 1999, he was the recipient of the Friesen-Rygiel Award for Outstanding Canadian Academic Discovery. In 2002, he was awarded the Gustav Killian Medal by the World Association of Bronchology for his pioneering contributions to the field of early lung cancer diagnosis. In 2007, he became the first MDS-Rix endowed Director of Early Lung Cancer Detection and Translational Research at the BC Cancer Agency. In 2008, he received the Distinguished Achievement Award and the Martin M. Hoffman Award for research excellence from the University of British Columbia. In 2008, Dr. Lam and his colleagues discovered a novel blood biomarker for early detection and surveillance of lung cancer after treatment—this marker is part of the multi-center Terry Fox Research Institute Pan-Canadian Early Lung Cancer Detection Study testing a multi-modal model to identify smokers at highest risk of lung cancer for combined spiral CT scan and autofluorescence bronchoscopy. In 2009, the International Association for the Study of Lung Cancer (IASLC) recognized Dr. Lam with the Joseph W. Cullen Award for life-time scientific achievements in prevention research of thoracic malignancies.

Jack Troia, Chief Financial Officer

Jack Troia was a partner at Deloitte & Touche for fourteen years and in public accounting for over twenty-five years. Mr. Troia was a National Director of the Financial Services Practice and responsible for the financial services practices in the local offices of Deloitte & Touche in Washington, DC and Milwaukee, Wisconsin. He has significant experience in accounting and auditing for public and private companies, mergers and acquisitions, initial and secondary public offerings, financial management, and general business matters. Over the years he has worked with a significant number of businesses, especially in all aspects of financial management, business planning, accounting, and information systems.

After retiring from Deloitte & Touche, Mr. Troia took a temporary position at Georgetown University as an adjunct professor. For over five years Mr. Troia was involved with dynamic growing companies as both COO and CFO. He was responsible for all financial and operating aspects including accounting, treasury, human resources, management information systems, and operations. As CFO of Genyous Biomed, Mr. Troia serves to lead the Company's financial planning and related strategies. Under this role he will also help to develop the financial planning and control organizations of the affiliated companies Omnitura Therapeutics and Vitala Therapeutics.

Dr. Karoly Nikolich, Ph.D., Chief Scientific Advisor

Dr. Karoly Nikolich currently serves as the Executive Director of the Neuroscience Institute at Stanford. Dr. Nikolich has over 20 years of biotechnology industry experience and is an expert in central nervous system therapeutics. Dr. Nikolich's industry experience includes founding AGY Therapeutics in 1998. AGY has been dedicated to the discovery and development of therapies for neurological and psychiatric diseases. Prior to founding AGY, Dr. Nikolich served as Vice President of Research at Lynx Therapeutics, Inc., a genomics company. Earlier, he worked in the research division of Genentech, Inc. for 12 years, where he initiated, established and directed Genentech's neuroscience research program and participated in product development. As Chief Scientific Advisor of Genyous Biomed, Dr. Nikolich helps to direct the Company's basic research in new therapies for chronic diseases with specific focus on neurological and psychiatric diseases.